AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01189461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegaptanib sodium
Description: Upon enrollment, all subjects will be treated in the study eye with pegaptanib sodium 0.3 mg at the investigators' discretion based on visual acuity assessment up to a maximum of 48 weeks. The minimum dosing interval between injections will be at least 6 weeks.
Study NCT02555085 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BIIB063
Description: Single ascending IV dose
Study NCT02555085 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single dose
Study NCT01219192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M2ES
Description: M2ES IV D1,8,15,21 every 28 days a cycle
Study NCT01219192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M2ES
Description: M2ES IV D1,8,15,21, every 28days a cyce.
Study NCT01219192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M2ES
Description: M2ES 45mg IV D1,8,15,22 28days a cycle
Study NCT01219192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M2ES 60mg
Description: M2ES 60mg IV D1,8,15,22 every 28days a cycle
Study NCT01215149 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad35-ENV vaccine
Description: Recombinant adenovirus serotype 35 vector vaccine 5x10\^10 vp, delivered IM
Study NCT05029258 — intervention group
Intervention type: PROCEDURE
Intervention: Biopsy of tumour
Description: Cervical tumour biopsy during treatment. This will be used for gene expression (RNA) analysis against a hypoxia associated gene signature.
Study NCT05029258 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MRI scans
Description: Multiple magnetic resonance imaging (MRI) scans before and during treatment using oxygen enhanced (OE) / tissues oxygen level dependent (TOLD) sequence
Study NCT01285479 — intervention group
Intervention type: DRUG
Intervention: Fingolimod
Description: fingolimod 0.5 mg/day, including generic versions of fingolimod
Study NCT04188548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3484356
Description: Administered orally
Study NCT04188548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Administered orally
Study NCT04188548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Administered orally
Study NCT04188548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpelisib
Description: Administered orally
Study NCT04188548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Administered intravenously
Study NCT04188548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aromatase Inhibitor (AI)
Description: Anastrozole or Exemestane or Letrozole administered orally (physician choice)
Study NCT04188548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Administered intravenously
Study NCT04299243 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Contact Lenses
Description: Contact lenses for vision correction
Study NCT04299243 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Contact Lenses
Description: Contact lenses for vision correction
Study NCT03811990 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cleveland Clinic Stress Free Now Meditations For Healers
Description: Phone-based meditation application
Study NCT01606423 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally, single dose
Study NCT01606423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2409021
Description: Administered orally, single dose
Study NCT04297332 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Intervention
Description: Complete active episodic thinking task
Study NCT04297332 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Intervention
Description: Complete active future thinking priming task
Study NCT04297332 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Intervention
Description: Complete control episodic future thinking task
Study NCT01215149 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.ENVA.01 vaccine
Description: Recombinant adenovirus serotype 26 vector vaccine, 5x10\^10 vp delivered IM
Study NCT04297332 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Intervention
Description: Complete control episodic future thinking task
Study NCT04297332 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Intervention
Description: Complete control future thinking priming task
Study NCT04297332 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Intervention
Description: Complete control future thinking priming task
Study NCT04297332 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Informational Intervention
Description: Provided with Forever Free relapse prevention booklet
Study NCT04297332 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Informational Intervention
Description: Provided with Forever Free relapse prevention booklet
Study NCT04297332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement
Description: Receive nicotine patches, gum, or lozenges
Study NCT04297332 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine Replacement
Description: Receive nicotine patches, gum, or lozenges
Study NCT04297332 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telephone-Based Intervention
Description: Receive coaching call
Study NCT04297332 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Telephone-Based Intervention
Description: Receive coaching call
Study NCT01749267 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: partial caries removal only at enamel dentin junction.
Description: Partial caries removal only at enamel dentin junction (EDJ) without carious dentin removal at the pulpal site and restoration with glass ionomer cement(SMART restoration)
Study NCT02356627 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The Cancer Home Life Intervention
Description: Adaptive interventions aiming at compensating for functional limitations.
Study NCT01215149 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo Control
Description: Colorless 10mm Tris/HCl buffer
Study NCT02107989 — intervention group
Intervention type: DEVICE
Intervention: MRI
Description: MRI of the brain is routinely used to identify abnormal areas of cortex in patients with medically refractory epilepsy. MRI evaluations of brain may be performed at field strengths of 1.5T, 3T, and/or 7T, under conditions designated by the FDA as constituting nonsignificant risk.
Study NCT02107989 — intervention group
Intervention type: DEVICE
Intervention: MEG
Description: MEG/EEG: Magnetoencephalography (MEG) is commonly used during epilepsy pre-surgical evaluations to help with localizing epileptic foci. MEG will be obtained as clinically indicated, usually in patients with unclear seizure focus localization who are undergoing presurgical evaluation, particularly when they have frequent interictal discharges on EEG. MEG records very small magnetic fields generated by the brain at rest, or in response to a task or to epileptic activity. Resting state MEG/EEG analysis will be used for research purposes only.
Study NCT03246347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADT+Docetaxel+Enzalutamide
Description: combination therapy as listed above
Study NCT02620852 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Complete a health questionnaire
Description: Complete a health history questionnaire.
Study NCT02620852 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Complete a health questionnaire
Description: Complete a health history questionnaire.
Study NCT02620852 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Provide a saliva sample for genetic testing
Description: Provide a saliva sample for testing of 9 genes and a panel of single nucleotide polymorphisms (SNPs) that influence breast cancer risk
Study NCT02620852 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Screening advice based on a comprehensive risk assessment
Description: Receive a screening schedule recommendation
Study NCT02620852 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Screening advice based on a basic risk assessment
Description: Receive a screening schedule recommendation
Study NCT04856735 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intraperİtoneal local anaesthesİc İn cesarean sectİon
Description: After the birth of the newborn and placenta, the uterus is closed and the blood accumulated in the pelvis is carefully wiped with surgical towels, after hemostasis is fully achieved, a total of 20 ml solution containing 10 cc of 0.5% bupivacaine +10 cc 2% lidocaine and 2 injectors containing 20ml saline and the 20ml solution were given to the surgeon area.
Study NCT04856735 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Local wound infiltrasyon
Description: A solution containing 20 ml of saline was added to all four quadrants of the uterus in 5 ml volume and 20 ml solution containing lidocaine and bupivacaine were subcutaneously in the form of LWI before the skin was closed
Study NCT04856735 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: One of the two sterile injectors containing 20 ml of saline was applied to the uterine peritoneal region and the other was applied to the incision area as a local subcutaneous wound infiltration.
Study NCT01385046 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Project Fit
Description: physical activity and nutrition education
Study NCT03815058 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autogene cevumeran
Description: Participants will receive a recommended dose of autogene cevumeran administered by IV infusion at protocol-defined intervals.
Study NCT03815058 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Participants will receive 200 mg pembrolizumab administered by IV infusion Q3W.
Study NCT03815058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Participants will receive 200 mg pembrolizumab administered by IV infusion Q3W.
Study NCT00398190 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Standard anti-tobacco programming
Study NCT00398190 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Media Literacy
Description: Anti-smoking media literacy curriculum intervention
Study NCT04198155 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic body radiotherapy (SBRT)
Description: Image-guided stereotactic body radiation therapy
Study NCT04091698 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Co-Enzyme Q10 mucoadhesive tablets
Description: will receive topical co enzyme q10 in the form of mucoadhesive tablets 3 times daily for 3months.
Study NCT04091698 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Co-Enzyme Q10 mucoadhesive tablets
Description: will receive topical co enzyme q10 in the form of mucoadhesive tablets 3 times daily for 3months.
Study NCT03564340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN4018
Description: REGN4018 will be administered in a series of dose escalation and dose expansion cohorts by intravenous (IV) infusion and/or subcutaneous (SC) as described in the protocol.
Study NCT03564340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cemiplimab
Description: Cemiplimab will be administered by IV infusion after REGN4018 monotherapy lead-in phase.
Study NCT03564340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sarilumab
Description: Sarilumab will be administered by IV, one-time-only, prior to IV/SC REGN4018.
Study NCT02155270 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Corneal precut 600µm
Study NCT02155270 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Corneal stabincision
Study NCT02369471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GWP42006
Study NCT02369471 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GWP42006
Study NCT02369471 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00919451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ciclosporin
Description: Ciclosporin 7.5mg/kg - reducing regimen over 24 weeks (additional prednisolone given for the first four weeks)
Study NCT03554408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10-1074-LS
Description: Subcutaneous injection of 10-1074-LS
Study NCT03554408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10-1074-LS
Description: Intravenous infusion of 10-1074-LS
Study NCT03554408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3BNC117-LS
Description: Subcutaneous injection of 3BNC117-LS
Study NCT03554408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3BNC117-LS
Description: Intravenous infusion of 3BNC117-LS
Study NCT02047162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bismuth subsalicylate
Study NCT02047162 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Chewable tablets identical to intervention tablets, but missing the bismuth subsalicylate
Study NCT01896765 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Prevention Program
Description: Study nurse-coordinated education sessions, telephone calls, telephone hotline and telemetric care of cardiovascular risk factors (if patient internet connection available).
Study NCT01896765 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard medical and interventional therapy
Description: Medical and interventional therapy following the standard of care.
Study NCT01896765 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard medical and interventional therapy
Description: Medical and interventional therapy following the standard of care.
Study NCT00663611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norditropin
Description: Norditropin (somatropin, rDNA origin) is a polypeptide hormone of recombinant DNA origin. The amino acid sequence of the product is identical to that of the human growth hormone of pituitary origin.
Study NCT00663611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% normal saline
Study NCT04115072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Praziquantel 600Mg Oral Tablet x 5
Description: Five doses of Praziquantel 40 mg/kg
Study NCT04115072 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Praziquantel 600Mg Oral Tablet x 1
Description: Single dose of Praziquantel 40 mg/kg
Study NCT03076905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F901318
Description: Evaluation of AUC0-t
Study NCT00258739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel + carboplatin + radiotherapy + docetaxel + gemcitabine
Description: Docetaxel 20 mg/m²/week with carboplatin AUC 2/week and concomitant radiotherapy up to 60 Gy. Further on, 2 Docetaxel cycles and gemcitabine according to arm 2.
Study NCT00258739 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Docetaxel + gemcitabine + carboplatin + radiotherapy
Description: Docetaxel 40 mg/ m² days 1, 8, 21 and 28 with gemcitabine 1200 mg/ m² days 1, 8, 21 and 28 followed by concomitant treatment with docetaxel 20 mg/m²/week with carboplatin AUC 2/week and concomitant radiotherapy up to 60 Gy (2 Gy/day, 5 days per week and for 6 weeks).
Study NCT01064362 — intervention group
Intervention type: DRUG
Intervention: Fondaparinux sodium
Description: Fondaparinux sodium for thromboprophylaxis (ATC: B01AX05)
Study NCT01064362 — intervention group
Intervention type: DRUG
Intervention: Low molecular weight heparin (LMWH)
Description: LMWH including: dalteparin, nadroparin, enoxaparin or tinzaparin (ATC:B01AB (excluding B01AB01))
Study NCT01504373 — intervention group
Intervention type: DEVICE
Intervention: Neurally Adjusted Ventilatory Assist (NAVA)
Description: Subjects will be placed in the NAVA mode of ventilation.
Study NCT01706432 — intervention group
Intervention type: RADIATION
Intervention: hyperfractionated radiation therapy
Description: Undergo hypofractionated radiation therapy
Study NCT01706432 — intervention group
Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01706432 — intervention group
Intervention type: RADIATION
Intervention: stereotactic radiosurgery
Description: Undergo stereotactic radiosurgery
Study NCT03086005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Study NCT03086005 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Study NCT03279601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine, Dacarbazine
Description: Capecitabine: 1000mg/m2 ，p.o. bid d1-14 q4W Dacarbazine: 200mg/m2 ，iv drip,d1-5 q4W
Study NCT03279601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine, Temozolomide
Description: Capecitabine: 1000mg/m2 ，p.o. bid d1-14 q4W, Temozolomide: 200mg/m2 ，p.o. bid d10-14 q4W,
Study NCT03327857 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Neihulizumab (ALTB-168)
Description: Single dose phase: Patients will receive single dose of Neihulizumab based on the protocol escalation criteria.~Multiple dose phase: Parients will receive weekly doses of Neihulizumab for 4 weeks.
Study NCT02805946 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: posaconazole
Description: iv versus oral
Study NCT03193229 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MapTrek
Description: The objective of the study is to provide an inexpensive and scalable m-health tool to increase both volume and intensity of physical activity and reduce sedentary behavior in patients at risk for or already diagnosed with pre-diabetes.
Study NCT03193229 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fitbit
Description: Fitbit
Study NCT03193229 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fitbit
Description: Fitbit
Study NCT03655600 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Self-administered acupressure
Description: Self-administered acupressure learned through app for reduction of need for opioids post-surgery in breast cancer patients
Study NCT03327038 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-Based Cognitive Behavioral Therapy
Description: Patients will receive access to a 5-week web-based CBT program entitled 'Mood Gym'. The program is derived from traditional, therapist-directed cognitive behavioral therapy. The program consists of 5 modules, and patients will asked to complete 1 module per week over, during weeks 2-6 over their intervention period.
Study NCT03327038 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Short Questionnaires
Description: Patients will receive emails to complete bi-weekly, web-based questionnaires at weeks 2, 4, and 6 of their intervention period. The short questionnaires will ask to patients to self-report their Depression (PHQ-9) and Anxiety (GAD-7) symptoms; along with their Crohn's Disease activity (PRO-2) or Ulcerative Colitis Disease Activity (MAYO-6).
Study NCT03327038 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse Monitoring
Description: Patient responses to the short questionnaires will be monitored by an IBD advanced practice nurse. The IBD nurse will determine if there are elevations in anxiety, depression, and disease activity over the intervention period. Based on patient responses to the short questionnaires, the nurse will follow-up with patients via email or telephone to address patient symptoms. If there are clinically important changes in the patients' disease activity the nurse may also arrange for the patients to receive expedited outpatient follow-up with their gastroenterologist.
Study NCT03327038 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Detailed Questionnaires
Description: Patients will complete a detailed questionnaires at enrollment (i.e. week 1 of enrollment) and also at post-intervention (i.e. week 8 of enrollment). The enrollment questionnaire will query the patients Ulcerative Colitis Disease Activity (MAYO-6) or Crohn's Disease Activity (PRO-2); Quality of Life (SIBDQ); and Patient Satisfaction with Health Care in IBD (CACHE). The post-intervention questionnaire will query the same information as the enrollment questionnaire but will also ask patients to self-report their depression (PHQ-9) and anxiety (GAD-7) symptoms.Quality of Life will be measured using the 10 item Short Inflammatory Bowel Disease Questionnaire (SIBDQ), which has a total score range of 10 to 70, with higher scores indicating better quality of life. Patient Satisfaction with Health Care in IBD will be measured using the 32 item CACHE Questionnaire, which scores from 0 -least satisfaction to 100-highest satisfaction.